Xspray Pharma publishes Interim report Q4, January – December 2020 . Regulatory press release 2021-02-17. Nomination Committee proposes Anders Ekblom as new Chairman of the Board in Xspray Pharma . Regulatory press release 2021-01-29. Number of shares and votes in Xspray Pharma . Regulatory press release 2021-01-26

Xspray Pharma byter börslista – ”Skulle kunna ta runt halva marknaden på bara ett par veckor”

Nomination Committee proposes Anders Ekblom as new Chairman of the Board in Xspray Pharma . Regulatory press release 2021-01-29. Number of shares and votes in Xspray Pharma . Regulatory press release 2021-01-26 Xspray Pharma offentliggör uppdatering om sin förbättrade version av dasatinib . Regulatoriskt pressmeddelande 2021-04-08.

Xspray pharma news

STOCKHOLM (Direkt) Xspray Pharma ser potential för en försäljning i miljardkronorsklassen för två av de tre produktkandidater inom cancerbehandlingar som 20 Jan 2021 11, Heidelberg Pharma, DE, +228.9 23, XSpray Pharma, SE, +133.2 This phenomenon, along with some non-COVID news, made our XSpray Pharma Aktie im Überblick: Realtimekurs, Chart, Fundamentaldaten, Diese NEWS-BOMBE läuft gerade über die TICKER: Zweite Bohrung liefert 21 okt 2020 Forskningsbolaget Xspray Pharma har genomfört en riktad nyemission som tillför 265 miljoner kronor före emissionskostnader. Xspray Pharma meddelar resultat från två bioekvivalensstudier med justerad tablettformulering av HyNap-Dasa (ANDA). Regulatoriskt pressmeddelande Originalbolagen kan efter att det primära patentet löper ut inte patentskydda sina produkter mot Xsprays varianter. Därför skapas ett flerårigt fönster där Xspray blir Kallelse till årsstämma i Xspray Pharma AB (publ). tis, apr 14, 2020 17:30 CET. Aktieägarna i Xspray Pharma AB (publ), org.nr 556649-3671, kallas till Xspray Pharma publicerar delårsrapport Q2, januari – juni 2019. tor, aug 29, 2019 08:00 CET. 2019-08-29 ”Vi har tidigare visat att det fungerar att tillverka små This company has moved to a main market, therfore we do not show updates relating to this company. News; Instruments Xspray Pharma AB (publ) engages in developing protein kinase inhibitors for targeted cancer treatments in Sweden.

NP3 Fastigheter AB. kr 135.20-0.73%. Senaste om Xspray Pharma: We give a short comment to the news that the clinical study with HyNap-Dasa will be delayed.

5 days ago Get the latest XSpray Pharma AB (publ) (XSPRAY) real-time quote, historical performance, charts, and other financial information to help you

Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) today announces that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation for its product candidate, HyNap-Nilo, for the treatment of chronic myeloid leukemia (CML).. HyNap-Nilo is under development as an improved version of TasignaTM (nilotinib), a leading drug for CML. The FDA's Orphan Drug Designation (ODD) has 2021-04-08 2020-06-03 Can Xspray Pharma Raise More Cash Easily? Since its cash burn is moving in the wrong direction, Xspray Pharma shareholders may wish to think ahead to when the company may need to raise more cash. Companies can raise capital through either debt or equity.

28 783 visningar. Idag 10:08. av badbollen3. 976. SynAct Pharma - SYNACT (82) · PeterFallman. Svar av nionittisexan Idag 08:54. 86 310 visningar • 976 svar.

Regulatory press release 2021-01-26 Xspray Pharma offentliggör uppdatering om sin förbättrade version av dasatinib . Regulatoriskt pressmeddelande 2021-04-08. Xspray Pharma meddelar resultat från två bioekvivalensstudier med justerad tablettformulering av HyNap-Dasa (ANDA) Regulatoriskt pressmeddelande 2021-03-19. Xspray Pharma publicerar årsredovisning för 2020 Senaste nyheter om - Xspray Pharma, aktieanalys, kursutveckling och rapporter.

That's decent, giving the company a couple years to develop its business. Find the latest Xspray Pharma AB (XSPRAY.ST) stock quote, history, news and other vital information to help you with your stock trading and investing. XSpray Pharma Registered News: This is the News-site for the company XSpray Pharma Registered on Markets Insider Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo, HyNap-Sora, and HyNap-Dasa.
Zara firmaland

Xspray Pharma AB (publ) ('Xspray' or the 'Company') has, based on the authorisation granted by the annual general meeting on 14 May 2020, and in accordance with that the Company indicated in a press release on 20 October 2020, successfully carried out a directed share issue at a subscription price of SEK 142.50 per share (the 'Issue'). Xspray Pharma AB (publ) is a product development company with multiple product candidates in clinical development.

Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. XSpray Pharma Proposes a Directed Issue of 1,350,000 Shares Corresponding to Approximately SEK 88 Million to Expand the Product Portfolio STOCKHOLM, Sweden, Jan. 30, 2018 /PRNewswire/ -- The board of directors of Xspray Pharma AB (publ) has resolved to propose a directed share issue of 1,350,000 shares at a subscription price of SEK 65 per share, representing a discount of 2 percent compared Xspray Pharma AB (publ) (“Xspray” or the “Company”) has, based on the authorisation granted by the annual general meeting on 14 May 2020, and in accordance with that the Company indicated in a press release on 20 October 2020, successfully carried out a directed share issue at a subscription price of SEK 142.50 per share (the “Issue”).
Lyft bilar

Interested in this type of news? Explore this Xspray Pharma får första produktpatentet för HyNap-Dasa i USA. Den 20 oktober, 2017 rapporterade Xspray Pharma att de har fått godkännande för ett sökt patent i USA. Patentet

XSpray Pharma AB (XSPRAY) Forum — Asarina pharma: studieresultatet för Cision News Ascelia pharma baktier. ACELP Synact pharma forum. Delårsrapport januari-juni 2019 - Avanza - Cision News Ascelia pharma baktier.

XSpray Pharma AB. Organisationsnummer 556649-3671. Namnändringar och notering på lista. År. Kommentarer. Aktien är noterad på Nasdaq Stockholm

Xspray Pharma belongs to the health care sector and is the 10 th company to be admitted to trading on Nasdaq’s Nordic markets* in 2020.

Xspray Pharma on LinkedIn, Twitter & YouTube Köp aktier i Xspray Pharma - enkelt och billigt hos Avanza Bank. Klicka här för att se aktiekursen och köpa till marknadens lägsta courtage. XSpray Pharma Proposes a Directed Issue of 1,350,000 Shares Corresponding to Approximately SEK 88 Million to Expand the Product Portfolio STOCKHOLM, Sweden, Jan. 30, 2018 /PRNewswire/ -- The board of directors of Xspray Pharma AB (publ) has resolved to propose a directed share issue of 1,350,000 shares at a subscription price of SEK 65 per share, representing a discount of 2 percent compared Xspray Pharma AB (publ) (“Xspray” or the “Company”) has, based on the authorisation granted by the annual general meeting on 14 May 2020, and in accordance with that the Company indicated in a press release on 20 October 2020, successfully carried out a directed share issue at a subscription price of SEK 142.50 per share (the “Issue”). Stock analysis for XSpray Pharma AB (XSPRAY:Stockholm) including stock price, stock chart, company news, key statistics, fundamentals and company profile.